Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD
Crossref DOI link:
Published Online: 2016-09-02
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fabbri, Leonardo M.
Kerwin, Edward M.
Ferguson, Gary T.
St. Rose, Earl
Funding for this research was provided by:
Pearl Therapeutics Inc., a member of the AstraZeneca Group (N/A)